Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Endocrinol Invest ; 42(7): 859-865, 2019 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-30519958

RESUMEN

PURPOSE: Chronic GC administration has numerous side effects, but little is known about the side effects of their short-term use (< 3 months)-particularly, when high doses are involved, as in the treatment of Graves' orbitopathy (GO). We investigated the effects of short-term, high-dose GC on bone turnover markers, bone mineral density (BMD), and trabecular bone scores (TBS). METHODS: Eleven patients (10 females and 1 male; median age 56 years) with active GO who were candidates for treatment with intravenous (iv) methylprednisone were consecutively enrolled. All patients were pretreated with a loading dose of 300,000 units of cholecalciferol, then given a median cumulative dose of 4.5 g (range 1.5-5.25 g) iv methylprednisone. Biochemical parameters of bone metabolism (25OHD3, PTH, P1NP, CTX and bALP) were measured at the baseline, and then 1 week and 1, 3, 6 and 12 months. BMD and TBS were obtained by X-ray absorptiometry (DXA) at the baseline and at 6 and 12 months. On DXA image, morphometric vertebral fracture assessment (VFA) was done. RESULTS: There were no significant changes in PTH, bALP or P1NP. A significant drop in CTX was seen at 1 month (down Δ49.31% from the baseline, p = 0.02), with a return to the baseline at the 3-month measurement. There was a moderate (not significant), but persistent reduction in P1NP. No changes in BMD or TBS came to light. No vertebral fractures were documented. CONCLUSIONS: Short-term, high-dose GC treatment caused a rapid, transient suppression of bone resorption, with no effects on BMD or bone micro-architecture (TBS).


Asunto(s)
Biomarcadores/análisis , Densidad Ósea/efectos de los fármacos , Resorción Ósea/prevención & control , Hueso Esponjoso/efectos de los fármacos , Glucocorticoides/administración & dosificación , Oftalmopatía de Graves/tratamiento farmacológico , Adulto , Anciano , Resorción Ósea/metabolismo , Femenino , Estudios de Seguimiento , Glucocorticoides/farmacología , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Proyectos Piloto , Pronóstico , Estudios Prospectivos
2.
J Endocrinol Invest ; 35(4): 419-24, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22453036

RESUMEN

Selenium (Se) is an important element that exerts its effects on the selenoproteins. It is an essential component of the glutathione peroxidase enzymes, which have anti-oxidant and anti-inflammatory properties, and a component of iodothyronine selenodeiodinases, which catalyze the extrathyroid production of T3 from T4. Se is important to several aspects of thyroid homeostasis and may influence the natural course of thyroid diseases such as autoimmune thyroiditis (AIT). This review analyzes the effects of Se supplementation in patients with AIT, based on the studies published on this issue to date.


Asunto(s)
Suplementos Dietéticos , Progresión de la Enfermedad , Selenio/uso terapéutico , Tiroiditis Autoinmune/tratamiento farmacológico , Tiroiditis Autoinmune/patología , Animales , Humanos , Ensayos Clínicos Controlados Aleatorios como Asunto/métodos , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA